文献速递肝病消化道肿瘤与早癌消化内镜

基于MRI预测HCC切除后1年内极早期复发:国际队列研究

MRI-based prediction of very early recurrence within 1 year after resection of HCC: An international cohort study.
PubMed 文献 · J Hepatol · 2026-06-20

本研究基于国际多中心1811例单发BCLC 0/A期HCC切除患者,开发并外部验证了MRI预测1年无复发生存率的MERP-pre和MERP-post模型。两模型在东方、西方及CT测试队列中C指数为0.685-0.790,优于主要分期系统和IMbrave050标准(0.524-0.682),并能区分高低危组。

要点

  • MERP-pre含AFP、肿瘤大小、门静脉期瘤周低强化和瘤内出血产物。
  • MERP-post以微血管侵犯替代肿瘤大小,两模型均优于现有预后系统。
  • MERP-pre低危组肿瘤呈非增殖类、脂质分解增强和免疫活跃微环境。

核心结论

  • MERP模型可稳健、泛化且具生物学依据地预测HCC切除后极早期复发,有助于细化风险分层管理。

研究设计与样本

  • 国际多中心回顾性队列研究,纳入14家医院1811例接受根治性切除的单发BCLC 0/A期HCC患者及TCGA-LIHC数据集40例。
  • 推导队列n=628,东方外部验证队列n=775,西方外部验证队列n=178,CT测试队列n=230。

主要发现

  • MERP-pre包含AFP、肿瘤大小、门静脉期瘤周低强化和瘤内出血产物;MERP-post以微血管侵犯替代肿瘤大小。
  • 两模型在所有测试队列中C指数为0.685-0.790,优于主要分期系统和IMbrave050标准的0.524-0.682(P值<0.001至0.046)。
  • MERP模型持续将患者分为高低危组,1年RFS率差异均有统计学意义(P<0.001)。
  • MERP-pre进一步改善基于MVI的风险重分类(NRI=0.323)和生存风险分层。
  • MERP-pre低危组肿瘤呈现非增殖类特征、脂质分解增强和免疫活跃微环境。

关键数值与推荐

  • MERP-pre预测1年RFS的C指数在测试队列为0.685-0.790,对照系统为0.524-0.682。
  • 风险重分类改善NRI范围为0.004-0.372。
  • MERP-pre改善MVI风险重分类的NRI为0.323。

临床怎么用

  • 对于单发BCLC 0/A期HCC拟行根治性切除者,可用术前MRI变量计算MERP-pre预测1年复发风险。
  • 术后获得MVI信息后可用MERP-post更新风险分层,辅助个体化随访和治疗决策。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Very early recurrence (within 1 year after resection) of hepatocellular carcinoma (HCC) indicates aggressive tumor biology and poor prognosis; however, non-invasive prediction tools remain scarce. This study aimed to develop and validate MRI-based models for predicting very early recurrence and to explore their biological underpinnings. METHODS: This international, multicenter cohort study retrospectively included 1,811 consecutive patients who underwent curative-intent resection for a single BCLC 0/A HCC and preoperative contrast-enhanced MRI or CT at 14 tertiary care hospitals in China, South Korea, Singapore, France, and the USA, as well as 40 eligible patients from the TCGA-LIHC dataset. To predict 1-year recurrence-free survival (RFS), MRI for Very Early Recurrence Prediction (MERP) models were developed using either preoperative variables alone (MERP-pre) or a combination of pre- and postoperative variables (MERP-post) in the derivation cohort (n = 628). The models were externally validated in Eastern (n = 775) and Western (n = 178) test cohorts and further evaluated in a CT test cohort (n = 230). Biological correlates were investigated using whole-exome and RNA sequencing. RESULTS: MERP-pre incorporated alpha-fetoprotein, tumor size, portal venous phase peritumoral hypoenhancement, and intratumoral blood products, whereas MERP-post replaced tumor size with microvascular invasion (MVI). Both models outperformed major staging systems and the IMbrave050 criteria across all test cohorts (C-index, 0.685-0.790 vs. 0.524-0.682; p values, <0.001 to 0.046) and improved risk reclassification (net reclassification improvement [NRI], 0.004-0.372). The MERP models consistently stratified patients into high- and low-risk groups with distinct 1-year RFS rates (all p <0.001). MERP-pre further improved MVI-based risk reclassification (NRI, 0.323) and survival risk stratification. Tumors classified as low risk by MERP-pre exhibited features of the non-proliferative class, increased lipid catabolism, and an immunoactive microenvironment. CONCLUSIONS: The MERP models may serve as robust, generalizable, and biologically informed tools for predicting very early HCC recurrence and may help refine risk-stratified management strategies. IMPACT AND IMPLICATIONS: Very early recurrence (VER) of hepatocellular carcinoma (HCC) within 1 year after resection reflects aggressive tumor biology and is associated with poor prognosis, yet reliable tools for predicting VER remain scarce. In this large, international, multicenter cohort of patients with a single Barcelona Clinic Liver Cancer stage 0/A HCC undergoing curative-intent resection, we developed and externally validated two MRI-based models (MERP-pre and MERP-post) that integrate routinely available clinicopathological and imaging variables. The MERP models consistently outperformed existing prognostic systems and effectively stratified patients into high- and low-risk groups with distinct 1-year recurrence-free survival across diverse cohorts. These findings highlight the potential of the MERP models to complement existing prognostic systems and optimize risk-stratified management of HCC.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Wei H, Heo S, Yang Y, et al. MRI-based prediction of very early recurrence within 1 year after resection of HCC: An international cohort study. J Hepatol. 2026. PMID: 42323021. doi:10.1016/j.jhep.2026.05.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。